News

VistaGen Therapeutics will begin a Phase 2 clinical trial to evaluate its lead candidate AV-101 as a potential treatment to reduce dyskinesia (abnormal involuntary movements) induced by levodopa in patients with Parkinson’s disease, after the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new…

The first three winners of the Parkinson’s Foundation’s new Physical Therapy Faculty Award will use their up to $10,000 grant for projects aimed at putting exercise to work in improving patients’ lives. The program underscores an increasing need, as more patients live longer, for physical therapists trained in Parkinson’s.

High levels of urate in the blood may help preserve dopamine-producing neurons and be used as a biomarker of positive outcomes in men newly-diagnosed with Parkinson’s disease, a study says. The study, “Sex dependent association of urate on the patterns of striatal dopamine depletion in…

A mutation in the ATP13A2 gene disrupts the transport of polyamines — positively charged molecules that interact with DNA and proteins to control cell growth, survival, and proliferation — killing nerve cells and potentially leading to Parkinson’s disease, a study reports. The study, “ATP13A2…

Zelira Therapeutics, an Australia-based medical cannabis company, has partnered with the Parkinson’s Foundation to learn more about patients’ usage and understanding of medical cannabis and hemp-derived treatments. Zelira and the organization are developing a survey looking at current use and perceived benefits of medical cannabis among those…

Elevated blood levels of the liver enzyme gamma-glutamyltransferase (GGT), a marker for liver disease, was found to be associated with an increased risk of Parkinson’s disease in Korean women and a lower risk in Korean men, a large-scale study  found.

Kevin Schaefer hadn’t been in an airport since he was 4 years old, so he had been looking forward to flying from his home in Cary, North Carolina, to Anaheim, California, in June for the 2019 Cure SMA Conference. As it turned out, his experience didn’t go as expected.

Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for Parkinson’s disease. SLS-007, originally developed by scientists at the University of California, Los Angeles, is intended to lessen the aggregation, or clumping, of alpha-synuclein protein —…

Bone marrow stem cells treated with fasudil and administered via the nose (intranasal) to mice in a model of Parkinson’s disease led to evidence of better motor abilities and a reduced of dopaminergic neurons,  a recent study from China reports. These results suggest that fasudil’s use and intranasal delivery…

The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company…